ID23172A - Metode yang diperbaiki untuk pengolahan protein c teraktivasi - Google Patents

Metode yang diperbaiki untuk pengolahan protein c teraktivasi

Info

Publication number
ID23172A
ID23172A IDW991254A ID991254A ID23172A ID 23172 A ID23172 A ID 23172A ID W991254 A IDW991254 A ID W991254A ID 991254 A ID991254 A ID 991254A ID 23172 A ID23172 A ID 23172A
Authority
ID
Indonesia
Prior art keywords
protein
improved method
private processing
private
processing
Prior art date
Application number
IDW991254A
Other languages
English (en)
Indonesian (id)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Jeffrey Clayton Baker
Lihua Huang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID23172A publication Critical patent/ID23172A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IDW991254A 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi ID23172A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
ID23172A true ID23172A (id) 2000-03-23

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW991133A ID22933A (id) 1997-04-28 1998-04-24 Fomulasi protien c terakivasi
IDW991254A ID23172A (id) 1997-04-28 1998-04-24 Metode yang diperbaiki untuk pengolahan protein c teraktivasi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IDW991133A ID22933A (id) 1997-04-28 1998-04-24 Fomulasi protien c terakivasi

Country Status (35)

Country Link
US (4) US6162629A (fr)
EP (2) EP0875563A3 (fr)
JP (2) JP4383546B2 (fr)
KR (2) KR100564189B1 (fr)
CN (2) CN1235638C (fr)
AR (2) AR015598A1 (fr)
AT (1) ATE285788T1 (fr)
AU (2) AU743531B2 (fr)
BR (2) BR9809304B1 (fr)
CA (2) CA2288143C (fr)
CO (2) CO4950523A1 (fr)
CZ (1) CZ298429B6 (fr)
DE (1) DE69828330T2 (fr)
DK (1) DK0875252T3 (fr)
EA (2) EA004881B1 (fr)
EG (1) EG23685A (fr)
ES (1) ES2234072T3 (fr)
HK (1) HK1016472A1 (fr)
HU (2) HU224826B1 (fr)
ID (2) ID22933A (fr)
IL (2) IL132502A0 (fr)
IN (2) IN183798B (fr)
MY (2) MY118591A (fr)
NO (2) NO995134L (fr)
NZ (2) NZ500346A (fr)
PE (2) PE86299A1 (fr)
PL (2) PL195642B1 (fr)
PT (1) PT875252E (fr)
SI (1) SI0875252T1 (fr)
SV (2) SV1998000051A (fr)
TR (2) TR199902529T2 (fr)
TW (2) TWI242443B (fr)
UA (2) UA73071C2 (fr)
WO (2) WO1998048818A1 (fr)
ZA (2) ZA983497B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR100564189B1 (ko) 1997-04-28 2006-03-27 일라이 릴리 앤드 캄파니 활성화 프로틴ｃ의 가공을 위한 개선된 방법
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
BR9915317A (pt) * 1998-11-13 2001-08-07 Lilly Co Eli Método de tratar trombocitopenia induzida por heparina
ES2195655T3 (es) * 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU1723200A (en) * 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
ATE264113T1 (de) * 1998-12-10 2004-04-15 Lilly Co Eli Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (fr) * 2000-05-24 2001-11-29 Eli Lilly And Company Preparations et techniques permettant de traiter des hypercoagulations
CA2438652A1 (fr) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (fr) 2001-09-19 2007-09-26 Oklahoma Med Res Found Traitement de la sepsie avec tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP2005528351A (ja) * 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
EP2283856B1 (fr) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Compositions solides stabilisées de polypeptides de facteur VIIa
US20060198894A1 (en) * 2002-10-29 2006-09-07 Johanna Bentz Stabilized, solid-state polypeptide particles
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004112828A1 (fr) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Composition liquide de polypeptides du facteur vii
US20080286279A1 (en) * 2004-03-17 2008-11-20 Chiron Corporation Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
WO2006014839A2 (fr) * 2004-07-23 2006-02-09 The University Of Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
CA2612859A1 (fr) * 2005-06-23 2006-12-28 The University Of British Columbia Polymorphismes de facteur de coagulation iii associes a une prediction relative aux resultats et a la reponse d'un sujet a une therapie
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
CA2654761A1 (fr) * 2006-06-09 2007-12-13 The University Of British Columbia Polymorphismes de l'interferon gamma utilises comme indicateurs de resultat chez des sujets gravement malades
ES2365832T3 (es) * 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
CA2904458C (fr) * 2007-11-30 2017-07-25 Wolfgang Fraunhofer Formulations de proteine et leurs procedes de fabrication
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2242875A4 (fr) * 2008-01-15 2012-04-04 Univ British Columbia Protéine c rs2069915 en tant que prédicteur de réponse de survie et administration de protéine c ou d'un composé de type protéine c activé
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
WO2013151727A1 (fr) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Compositions d'agents de charge d'héparine et procédés associés
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
WO2014005183A1 (fr) 2012-07-04 2014-01-09 The University Of Sydney Traitement de troubles cutanés inflammatoires
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3137102B1 (fr) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc pour l'utilisation dans le traitement de cicatrices cutanées anormales
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
UA123020C2 (uk) * 2016-06-01 2021-02-03 Сервьє Айпі Юкей Лімітед Склади поліалкіленоксид-аспарагінази та способи їхнього виготовлення й використання
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (fr) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Proteine c activee a chaine legere tronquee
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (fr) 1995-11-30 1997-06-05 Zymogenetics, Inc. Production de proteine c chez des animaux transgeniques
KR100564189B1 (ko) 1997-04-28 2006-03-27 일라이 릴리 앤드 캄파니 활성화 프로틴ｃ의 가공을 위한 개선된 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CN1235638C (zh) 2006-01-11
CN1261280A (zh) 2000-07-26
JP2001527543A (ja) 2001-12-25
CO4940438A1 (es) 2000-07-24
DK0875252T3 (da) 2005-04-25
CA2287267A1 (fr) 1998-11-05
UA73071C2 (en) 2005-06-15
PL195090B1 (pl) 2007-08-31
CN1227025C (zh) 2005-11-16
AU7258998A (en) 1998-11-24
ZA983497B (en) 1999-10-25
PL195642B1 (pl) 2007-10-31
IL132325A0 (en) 2001-03-19
HUP0003401A3 (en) 2003-01-28
AR015598A1 (es) 2001-05-16
NO995134D0 (no) 1999-10-21
US6395270B1 (en) 2002-05-28
CA2288143A1 (fr) 1998-11-05
ES2234072T3 (es) 2005-06-16
TR199902631T2 (xx) 2000-01-21
NO995198L (no) 1999-10-25
SV1998000050A (es) 1999-01-13
HUP0003401A2 (hu) 2001-02-28
IN187157B (fr) 2002-02-16
EG23685A (en) 2007-05-09
MY118591A (en) 2004-12-31
NO995134L (no) 1999-12-21
SI0875252T1 (en) 2005-06-30
EA002149B1 (ru) 2001-12-24
EP0875563A3 (fr) 2000-08-02
ID22933A (id) 1999-12-16
KR20010020242A (ko) 2001-03-15
JP2001524111A (ja) 2001-11-27
HUP0100284A3 (en) 2003-08-28
PL336420A1 (en) 2000-06-19
EP0875563A2 (fr) 1998-11-04
IL132325A (en) 2005-07-25
PE86299A1 (es) 1999-09-17
PT875252E (pt) 2005-03-31
IL132502A0 (en) 2001-03-19
ZA983496B (en) 1999-10-25
EA004881B1 (ru) 2004-08-26
PE84799A1 (es) 1999-09-16
WO1998048818A1 (fr) 1998-11-05
EA199900979A1 (ru) 2000-06-26
AU740753C (en) 2002-10-10
US6162629A (en) 2000-12-19
CN1254284A (zh) 2000-05-24
DE69828330D1 (de) 2005-02-03
BR9809292A (pt) 2000-07-04
KR100450856B1 (ko) 2004-10-02
CA2287267C (fr) 2006-08-15
TWI242443B (en) 2005-11-01
AU743531B2 (en) 2002-01-31
NZ500346A (en) 2001-08-31
EP0875252B1 (fr) 2004-12-29
EP0875252A3 (fr) 2000-07-26
TW585871B (en) 2004-05-01
DE69828330T2 (de) 2005-10-13
PL336889A1 (en) 2000-07-17
AR012010A1 (es) 2000-09-13
KR20010020325A (ko) 2001-03-15
HU224826B1 (en) 2006-02-28
CA2288143C (fr) 2012-08-21
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
HUP0100284A2 (hu) 2001-06-28
CZ298429B6 (cs) 2007-10-03
NO995198D0 (no) 1999-10-25
TR199902529T2 (xx) 2000-02-21
EP0875252A2 (fr) 1998-11-04
HK1016472A1 (en) 1999-11-05
IN183798B (fr) 2000-04-15
US6159468A (en) 2000-12-12
NZ337828A (en) 2001-06-29
EA199900980A1 (ru) 2000-04-24
KR100564189B1 (ko) 2006-03-27
BR9809304A (pt) 2000-10-17
CZ381099A3 (cs) 2000-03-15
BR9809304B1 (pt) 2011-02-08
WO1998048822A1 (fr) 1998-11-05
JP4383546B2 (ja) 2009-12-16
ATE285788T1 (de) 2005-01-15
AU740753B2 (en) 2001-11-15
SV1998000051A (es) 1998-12-11
CO4950523A1 (es) 2000-09-01
MY120984A (en) 2005-12-30
US6436397B1 (en) 2002-08-20
AU7161898A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
ID23172A (id) Metode yang diperbaiki untuk pengolahan protein c teraktivasi
DE69834209D1 (de) Bildverarbeitungsverfahren
FI971620A (fi) Autentikointimenetelmä
IS8368A (is) Ný aðferð
DE69836142D1 (de) Bildverarbeitungsnetz
DE69722620D1 (de) Nicht-waessrige protische peptidzubereitungen
DE69700307D1 (de) Ersatzverarbeitungsverfahren
DE69719859D1 (de) Bildverarbeitungsverfahren
IT1293092B1 (it) Marmitta di scarico
ID22755A (id) Proses prapengolahan kosmetik bekas
NO985680L (no) Peptidderivater
IS5106A (is) Ný aðferð
DE69718808D1 (de) Plasmabehandlungsmethode
NO983849D0 (no) Peptidderivater
ID27483A (id) Metoda terapi gen
ID23871A (id) Pembersih bagian pengolahan
DE69729051D1 (de) Bearbeitungsbetriebsmethode
DE69829102D1 (de) Reinigerlose Bilderzeugungsmethode
ID24830A (id) Proses untuk pengolahan laktam
DE59803086D1 (de) Elektrolyseapparat
NO20003079D0 (no) Polymerisasjon-oppstartningsprosess
DE69925271D1 (de) Angiostatin-bindendes protein
ID16924A (id) Metode perlakuan poliolefin
DE69836476D1 (de) Ionenimplantationsverfahren
DE69724736D1 (de) Prozessablaufsteuerung